GlassScriptPhysician profile
Joyce B Burton
NPI 1306803895
$3,616.66
in general payments reported to CMS, 2019-2025
16 companies · $991 in 2025
The $991 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $120 · 2021: $355 · 2022: $657 · 2023: $367 · 2024: $866 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,224.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $823.39 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $795.83 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $499.27 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $461.38 | 2021-2024 | |
| Lilly USA, LLC | $407.12 | 2020-2025 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $167.94 | 2022 | |
| Amgen INC. | $145.38 | 2024-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $132.93 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.65 | 2022 | |
| Novartis Pharmaceuticals Corporation | $34.19 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $27.85 | 2021 | |
| Astellas Pharma US INC | $20.89 | 2020 | |
| Jazz Pharmaceuticals INC. | $18.54 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.99 | 2020 | |
| Amarin Pharma, INC. | $15.31 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $15.00 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Burton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.